10/15/2021 8:37:41 AM
AbbVie Receives CHMP Positive Opinion For Risankizumab For Treatment Of Adults With Active Psoriatic Arthritis
10/7/2021 8:19:04 AM
AbbVie's RINVOQ Meets Primary And Secondary Endpoints In Phase 3 Study For Non-Radiographic Axial Spondyloarthritis
9/30/2021 9:55:37 AM
AbbVie Presents Late-Breaking Data On Risankizumab In Psoriatic Arthritis
9/30/2021 8:33:25 AM
AbbVie Presents Analyses Evaluating RINVOQ In Atopic Dermatitis Across Patient Characteristics And Body Regions
9/23/2021 8:51:25 AM
AbbVie Presents New Data Analyses For Growing Dermatology Portfolio
9/20/2021 9:14:51 AM
AbbVie Submits Application To FDA For SKYRIZI For Treatment Of Patients 16 Yrs And Older With Severe Crohn's Disease
9/16/2021 8:03:30 AM
AbbVie Submits Regulatory Applications To FDA And EMA For Upadacitinib For Active Ulcerative Colitis Treatment
9/13/2021 6:33:23 AM
AbbVie, REGENXBIO Form Strategic Deal, To Combine Eye Care And Gene Therapy
9/10/2021 3:50:36 PM
AbbVie (ABBV) Declares Quarterly Dividend of $ 1.30, Record Date 10/15/2021
9/10/2021 10:31:11 AM
AbbVie Declares Quarterly Dividend Of $1.30/shr; Payable November 15/record October 15
9/9/2021 7:04:29 AM
Genmab, AbbVie: The Lancet Publishes Trial Results Of Epcoritamab In Patients With R/r B-cell Non-Hodgkin's Lymphoma